Glycogen storage disease (GSD) – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2019 To 2030

Indication name: Glycogen storage disease (GSD)

Glycogen storage disease (GSD) – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2019 To 2030; (Markets covered: US, Germany, France, Spain, United Kingdom, Italy, Japan & China)

Glycogen storage disease (GSD) is a genetic condition in which the body has an enzyme problem and is not able to store or break down the complex sugar glycogen properly. There are at least 10 different types of GSDs. The types are put into groups based on the enzyme that is missing. The most common forms of GSD are- GSD I (lack of the enzyme Glucose-6-Phosphatase), GSD II (lack of the debrancher enzyme), GSD IV (an increased amount of glycogen in the tissues).

According to Thelansis the overall incidence of GSD (all forms) in Europe, Canada, and the United States is estimated to be between 1 in 18,000 and 1 in 45,000 and most IX is the most common form GSD caused by a deficiency of phosphorylase kinase system.

Competitive landscape of Glycogen storage disease (GSD) includes country specific approved as well as pipeline therapies. Any asset/ product specific designation or review and Accelerated Approval are being tracked and supplemented with analyst commentary.

KOLs insights of Glycogen storage disease (GSD) across 8 MM market from center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm and Unmet needs.

Glycogen storage disease (GSD) Market Forecasting: Patient Based Forecast Model (MS. Excel Based Automated Dashboard) which Data Inputs with sourcing, Market Event and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden and pricing scenario, Summary and Insights.

Read more: Glycogen storage disease (GSD) – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2019 To 2030

S. N.        Asset        Company                Stage

1        UX053        Ultragenyx Pharmaceutical Inc Phase 2

2        ORL-1G - D-galactose        Orpha Labs        Phase 2

3        GZ402666        Genzyme, a Sanofi Company        Phase 3

4        REN001         Reneo Pharma Ltd Phase 1

5        AT845        Audentes Therapeutics Phase 2

6        AAV2/8LSPhGAA        Asklepios Biopharmaceutical, Inc. Phase 2

7        ATB200 and AT2221 Amicus Therapeutics Phase 2

8        BMN 701         BioMarin Pharmaceutical Phase 2

9        SPK-3006         Spark Therapeutics Phase 2